Patents Examined by Kevin E. Weddington
  • Methods of treating overweight and obesity
    Patent number: 11139056
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
    Type: Grant
    Filed: September 2, 2019
    Date of Patent: October 5, 2021
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventors: Preston Klassen, Kristin Taylor
  • Solid dispersion forms of rifaximin
    Patent number: 11129817
    Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: September 28, 2021
    Assignee: Salix Pharmaceuticals, Inc.
    Inventors: Pam Golden, Mohammed A. Kabir
  • Methods and compositions for treating diseases related to imbalance of essential fatty acids
    Patent number: 11129842
    Abstract: This invention relates to compositions containing combinations of a balanced phosphatidylcholine composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from an imbalance of fatty acids and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: September 28, 2021
    Assignee: BODYBIO INC
    Inventors: Edward Kane, Patricia Kane, Brett T Hauser
  • Method of treatment
    Patent number: 11123349
    Abstract: The present invention relates to the treatment of equine animals presenting with an inflammatory condition and/or symptoms associated with inflammation and/or which have a condition which could lead to an inflammatory disorder. Formulations and therapeutic protocols useful for the treatment of inflammation and amelioration of symptoms associated with inflammation also form part of the present invention.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: September 21, 2021
    Assignee: THE UNIVERSITY OF MELBOURNE
    Inventor: Simon R. Bailey
  • Method for the treatment of osteoarthritis
    Patent number: 11123354
    Abstract: The present invention relates to a composition for use in the treatment of osteoarthritis (OA), wherein said composition comprises from 5 to 40 mg of sodium chlodronate, or an equivalent amount of chlodronic acid, or other pharmaceutically acceptable salts thereof, and wherein said composition is administered intra-articularly in a unitary dosage form once monthly, once biweekly or once weekly. Single-dose medicaments and kits comprising them are also described.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 21, 2021
    Assignee: ABIOGEN PHARMA S.P.A.
    Inventors: Fabio Neggiani, Silvia Trasciatti
  • 2-amino-N'-benzylideneacetohydrazides and derivatives for the management of CFTR protein mediated diseases
    Patent number: 11116736
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N?-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is ((E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: September 14, 2021
    Assignees: Emory University, Bar-Ilan University, Children's Healthcare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
  • Pharmaceutical composition
    Patent number: 11110062
    Abstract: An object of the present invention is to provide a pharmaceutical composition which has excellent stability, disintegratability, and absorbability, is easily prepared, and contains 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof and a cyclodextrin derivative. The present invention relates to a pharmaceutical composition containing 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof and hydroxypropyl-?-cyclodextrin.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: September 7, 2021
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Shinji Okada
  • Benzothia(di)azepine compounds and their use as bile acid modulators
    Patent number: 11111224
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: September 7, 2021
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Combination therapy
    Patent number: 11103469
    Abstract: The invention relates to a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, for use in treating type 2 diabetes. The invention also relates to the use of a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes. The invention also relates to a method of treating type 2 diabetes using a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 31, 2021
    Assignee: Novartis AG
    Inventors: Päivi M. Paldánius, Wolfgang Kothny, James E. Foley, David R. Matthews, Michael Stumvoll, Stefano Del Prato
  • Combination treatment of cancer
    Patent number: 11103481
    Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: August 31, 2021
    Assignee: Scandion Oncology A/S
    Inventors: Nils Aage Brünner, Palle Christophersen, Jan Stenvang, Jens Lichtenberg, Annemette Thougaard
  • Injectable phenol formulations and methods of manufacture
    Patent number: 11083695
    Abstract: Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: August 10, 2021
    Assignee: SAOL INTERNATIONAL DEVELOPMENT LTD.
    Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, Imran Ahmed, David Penake
  • Injectable phenol formulations and methods of their use
    Patent number: 11083694
    Abstract: Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: August 10, 2021
    Assignee: SAOL INTERNATIONAL DEVELOPMENT LTD.
    Inventors: Leonard O'Mahony, Sharon Hamm, John Devane, Imran Ahmed, David Penake
  • Preparation method therefor
    Patent number: 11083721
    Abstract: The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: August 10, 2021
    Assignee: Shenzhen Pharmacin Co., Ltd.
    Inventors: Zeren Wang, Yulan Zhao, Lijiang Wang, Xiao Zhang, Jun Xu, Shunqin Chen, Meili Sun, Guisheng Jiang
  • 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol and use thereof in the treatment of cancer
    Patent number: 11078191
    Abstract: This invention relates to an active metabolite of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimindin-4-amine that modulates the activity of adenosine A2a receptor. In particular, the present invention relates to pharmaceutical compositions comprising 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)-pyrimidin-2-yl)-1H-pyrazol-4-ol, as well as processes for its preparation and its use in the treatment of cancer alone of in combination with one or more immunotherapeutic agents.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: August 3, 2021
    Assignees: Novartis AG, Palobiofarma S.L.
    Inventors: Sanela Bilic, Juan Alberto Camacho Gomez, John Scott Cameron, Julio Cesar Castro-Palomino Laria, Danny Roland Howard, Jr.
  • Pharmaceutical composition
    Patent number: 11077062
    Abstract: An object of the present invention is to provide a pharmaceutical composition which has excellent stability, disintegratability, and absorbability, is easily prepared, and contains 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof and a cyclodextrin derivative. The present invention relates to a pharmaceutical composition containing 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof and hydroxypropyl-?-cyclodextrin.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: August 3, 2021
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Shinji Okada
  • Compositions and methods for treating chronic inflammation and inflammatory diseases
    Patent number: 11065218
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: July 20, 2021
    Assignee: Infirst Healthcare Limited
    Inventors: Robin Mark Bannister, John Brew, Wilson Caparros-Wanderley, Gregory Alan Stoloff, Suzanne Jane Dilly, Gemma Szucs, Olga Pleguezuelos Mateo
  • Anti-pathogenic therapeutic compositions
    Patent number: 11065220
    Abstract: Therapeutic compounds useful for the treatment of pathogens including bacteria (gram positive and gram negative, mycobacteria), some fungi and viruses. The compounds described herein may include a mixture of therapeutically-effective amounts of a polar amino acid, a CI 1 fatty acid, and an anthraquinone. The invention further provides for the administration of the therapeutic compounds to a patient (e.g., a human) suffering from an infection.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: July 20, 2021
    Assignee: Wintermute Biomedical, Inc.
    Inventors: Weston J. Hale, Thomas F. Rau
  • Therapeutic agent for tumors identified by phosphorylation of proto-oncogene protein belonging to VAV family
    Patent number: 11058685
    Abstract: The present invention provides a therapeutic agent and others for various tumors including angioimmunoblastic T-cell lymphoma (AITL), which is an orphan disease. The present invention relates to a therapeutic agent and others for tumors identified by phosphorylation of a proto-oncogene protein belonging to the VAV family, which comprises dasatinib or a prodrug thereof or a pharmacologically acceptable salt thereof or a hydrate or solvate thereof as an active ingredient.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: July 13, 2021
    Assignee: UNIVERSITY OF TSUKUBA
    Inventors: Shigeru Chiba, Mamiko Yanagimoto
  • Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders
    Patent number: 11058663
    Abstract: Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: July 13, 2021
    Assignee: Avoscience, LLC
    Inventor: Samuel Richard Huber
  • Compositions and methods for treatment of inflammation
    Patent number: 11058655
    Abstract: The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response. In particular, the anti-inflammatory immunomodulators are useful for treating an inflammatory condition or an autoimmune disease.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: July 13, 2021
    Assignees: Vireo Systems, Inc., Creighton University
    Inventors: Thomas McDonald, Kristen Drescher